{
  "name": "viralintegration-hpv-integration",
  "title": "HPV & Oncovirus Analysis",
  "description": "Detect viral DNA integration sites in host genomes using chimeric read analysis. Identifies HPV and other oncovirus integration events critical for cancer development, particularly in cervical and head/neck cancers. Samplesheet format: `ID,tumor`",
  "version": "0.1.1",
  "engineType": "NEXTFLOW",
  "command": "nextflow run nf-core/viralintegration --input ${input} --outdir ${outdir} -r 0.1.1",
  "imageUrl": "https://raw.githubusercontent.com/nf-core/viralintegration/master/docs/images/nf-core-viralintegration_logo_light.png",
  "content": "<h2><strong>Viral Integration Detection - HPV & Oncovirus Analysis</strong></h2><p>Identify viral DNA integration sites in host genomes using chimeric read analysis. Detects HPV and other oncovirus integration events that drive cancer development, with applications in cervical, head/neck, and other virus-associated cancers.</p><h3><strong>What is Viral Integration?</strong></h3><blockquote><p><strong>Viral integration</strong> occurs when viral DNA inserts into the host genome, disrupting normal cellular functions. For HPV and other oncoviruses, integration is a critical step in cancer development, often disrupting tumor suppressor genes or activating oncogenes.</p></blockquote><h3><strong>Why Detect Viral Integration?</strong></h3><ul><li><strong>Cancer Diagnostics</strong>: Integration sites identify high-risk HPV infections progressing to cancer</li><li><strong>Prognosis</strong>: Integration patterns correlate with disease severity and outcomes</li><li><strong>Treatment Selection</strong>: Integration status informs therapeutic strategies</li><li><strong>Mechanism Discovery</strong>: Reveals how viruses drive oncogenesis</li><li><strong>Biomarker Development</strong>: Integration signatures as disease biomarkers</li></ul><h3><strong>Key Features</strong></h3><ul><li><strong>Chimeric Read Detection</strong>: Identifies reads spanning viral-host genome junctions</li><li><strong>Multi-Virus Support</strong>: Detects HPV, EBV, HBV, HHV-8, and other oncoviruses</li><li><strong>Precise Localization</strong>: Pinpoints exact integration breakpoints</li><li><strong>Comprehensive QC</strong>: Quality assessment and trimming with FastQC</li><li><strong>Interactive Visualization</strong>: Genome browser views of integration sites</li><li><strong>Abundance Quantification</strong>: Viral load estimation across samples</li></ul><h3><strong>Pipeline Workflow</strong></h3><ol><li><strong>Quality Control</strong>: FastQC assessment of raw sequencing reads</li><li><strong>Read Trimming</strong>: Adapter removal and quality filtering</li><li><strong>Host Alignment</strong>: Map reads to human reference genome</li><li><strong>Viral Read Extraction</strong>: Identify reads with viral sequences</li><li><strong>Chimeric Read Detection</strong>: Find reads spanning viral-host junctions</li><li><strong>Integration Site Mapping</strong>: Determine precise breakpoint coordinates</li><li><strong>Verification</strong>: Validate candidate integration events</li><li><strong>Visualization</strong>: Interactive genome viewers and summary plots</li></ol><h3><strong>HPV Integration in Cancer</strong></h3><table><tr><th>Cancer Type</th><th>HPV Integration Rate</th><th>Key Features</th></tr><tr><td><strong>Cervical Cancer</strong></td><td>~85% of cases</td><td>Integration disrupts E2, leading to E6/E7 overexpression</td></tr><tr><td><strong>Head & Neck Cancer</strong></td><td>~60% of HPV+ cases</td><td>Oropharyngeal cancers, better prognosis when HPV+</td></tr><tr><td><strong>Anal Cancer</strong></td><td>~90% of cases</td><td>HPV16 most common, integration in MACROD2</td></tr><tr><td><strong>Penile Cancer</strong></td><td>~50% of cases</td><td>Integration associated with aggressive subtypes</td></tr></table><h3><strong>Common Integration Hotspots</strong></h3><ul><li><strong>MACROD2</strong>: Most frequent integration site in cervical cancer</li><li><strong>MIPOL1/TTC6</strong>: Second most common target, chromosome 14</li><li><strong>TP63</strong>: Tumor protein, integration alters expression</li><li><strong>FHIT</strong>: Fragile histidine triad gene, tumor suppressor</li><li><strong>RAD51B</strong>: DNA repair gene disruption</li><li><strong>Intergenic Regions</strong>: ~40% of integrations occur outside genes</li></ul><h3><strong>Oncogenic Mechanisms</strong></h3><ul><li><strong>E2 Disruption</strong>: Integration breaks E2 gene, removing E6/E7 repression</li><li><strong>E6/E7 Overexpression</strong>: Viral oncoproteins inactivate p53 and pRb</li><li><strong>Tumor Suppressor Loss</strong>: Integration disrupts genes like FHIT, MACROD2</li><li><strong>Genomic Instability</strong>: Integration triggers chromosomal rearrangements</li><li><strong>Gene Fusion</strong>: Viral-host gene fusions with altered function</li></ul><h3><strong>Supported Oncoviruses</strong></h3><ul><li><strong>HPV (Human Papillomavirus)</strong>: HPV16, HPV18, and other high-risk types</li><li><strong>EBV (Epstein-Barr Virus)</strong>: Nasopharyngeal carcinoma, lymphomas</li><li><strong>HBV (Hepatitis B Virus)</strong>: Hepatocellular carcinoma</li><li><strong>HHV-8 (Kaposi's Sarcoma Herpesvirus)</strong>: Kaposi's sarcoma</li><li><strong>HTLV-1</strong>: Adult T-cell leukemia/lymphoma</li><li><strong>MCPyV (Merkel Cell Polyomavirus)</strong>: Merkel cell carcinoma</li></ul><h3><strong>Input Requirements</strong></h3><p>CSV or TSV samplesheet with the following columns:</p><ul><li><strong>sample</strong>: Unique sample identifier (e.g., patient ID, tumor specimen)</li><li><strong>fastq_1</strong>: Path to Read 1 FASTQ file</li><li><strong>fastq_2</strong>: Path to Read 2 FASTQ file (for paired-end data)</li></ul><p><strong>Example samplesheet:</strong></p><pre>sample,fastq_1,fastq_2\nCervix_Tumor_01,tumor01_R1.fq.gz,tumor01_R2.fq.gz\nCervix_Tumor_02,tumor02_R1.fq.gz,tumor02_R2.fq.gz\nOropharynx_01,oropharynx01_R1.fq.gz,oropharynx01_R2.fq.gz</pre><h3><strong>Sequencing Requirements</strong></h3><ul><li><strong>Data Type</strong>: Whole genome sequencing (WGS) or targeted viral capture</li><li><strong>Coverage</strong>: 30-60x for WGS, 500-1000x for targeted enrichment</li><li><strong>Read Type</strong>: Paired-end recommended (2x100bp or 2x150bp)</li><li><strong>Quality</strong>: High-quality Illumina data (Phred >30)</li><li><strong>Library Size</strong>: 300-500bp insert size for optimal chimeric read detection</li></ul><h3><strong>Main Outputs</strong></h3><ul><li><strong>Integration Site Coordinates</strong>: BED/VCF files with breakpoint positions</li><li><strong>Chimeric Read Evidence</strong>: BAM files with supporting reads</li><li><strong>Viral Abundance</strong>: Read counts and copy number per sample</li><li><strong>Interactive Genome Viewers</strong>: IGV-compatible tracks for visualization</li><li><strong>Integration Summary Tables</strong>: Gene annotations, breakpoint details</li><li><strong>Quality Control Reports</strong>: MultiQC with alignment and detection metrics</li><li><strong>Visualization Plots</strong>: Integration frequency, hotspot heatmaps</li></ul><h3><strong>Integration Pattern Analysis</strong></h3><ul><li><strong>Integration Frequency</strong>: How many integration events per sample?</li><li><strong>Breakpoint Distribution</strong>: Where in the viral genome do breakpoints occur?</li><li><strong>Host Gene Disruption</strong>: Which cellular genes are affected?</li><li><strong>Clonality</strong>: Is integration clonal (early event) or subclonal (late)?</li><li><strong>Viral-Host Orientation</strong>: Sense or antisense integration?</li></ul><h3><strong>Clinical Applications</strong></h3><ul><li><strong>Risk Stratification</strong>: Integration predicts progression from infection to cancer</li><li><strong>Screening</strong>: Detect high-risk HPV infections requiring intervention</li><li><strong>Treatment Planning</strong>: Integration status influences therapy choice</li><li><strong>Monitoring</strong>: Track integration patterns during treatment</li><li><strong>Prognosis</strong>: Integration in specific genes correlates with outcomes</li><li><strong>Liquid Biopsy</strong>: Detect circulating tumor DNA with integration signatures</li></ul><h3><strong>Research Applications</strong></h3><ul><li><strong>Carcinogenesis Studies</strong>: Understand viral oncogenesis mechanisms</li><li><strong>Hotspot Discovery</strong>: Identify recurrent integration sites across patients</li><li><strong>Functional Genomics</strong>: Study effects of integration on gene expression</li><li><strong>Evolutionary Analysis</strong>: Track integration events during tumor evolution</li><li><strong>Biomarker Development</strong>: Identify integration signatures for diagnostics</li></ul><h3><strong>Chimeric Read Detection</strong></h3><p>The pipeline identifies three types of evidence:</p><ol><li><strong>Split Reads</strong>: Single reads mapping partially to host and viral genomes</li><li><strong>Discordant Read Pairs</strong>: Mate pairs where one maps to host, one to virus</li><li><strong>Soft-Clipped Reads</strong>: Reads with unmapped tails matching viral sequences</li></ol><h3><strong>Quality Control Metrics</strong></h3><ul><li><strong>Viral Read Abundance</strong>: Total viral reads per sample</li><li><strong>Chimeric Read Count</strong>: Number of integration-supporting reads</li><li><strong>Breakpoint Confidence</strong>: Support from multiple read types</li><li><strong>Mapping Quality</strong>: Alignment scores for host and viral regions</li><li><strong>Coverage Uniformity</strong>: Even coverage across viral and host regions</li></ul><h3><strong>Technical Considerations</strong></h3><ul><li><strong>Integration Detection Sensitivity</strong>: Requires sufficient sequencing depth</li><li><strong>False Positives</strong>: Can arise from viral contamination or PCR artifacts</li><li><strong>Low Clonality Events</strong>: Subclonal integrations need higher coverage</li><li><strong>Complex Rearrangements</strong>: Multiple integration sites or inversions</li><li><strong>Reference Genome</strong>: Accurate host and viral reference sequences required</li></ul><h3><strong>Comparison with Other Methods</strong></h3><table><tr><th>Method</th><th>Advantages</th><th>Limitations</th></tr><tr><td><strong>WGS + viralintegration</strong></td><td>Genome-wide, unbiased detection</td><td>Expensive, requires high coverage</td></tr><tr><td><strong>Targeted Capture</strong></td><td>Cost-effective, deep coverage</td><td>Requires known viral sequences</td></tr><tr><td><strong>PCR-based</strong></td><td>Quick, inexpensive</td><td>Requires known integration sites</td></tr><tr><td><strong>Southern Blot</strong></td><td>Gold standard validation</td><td>Low throughput, labor intensive</td></tr></table><h3><strong>Validation Strategies</strong></h3><ul><li><strong>PCR Confirmation</strong>: Design primers spanning integration junctions</li><li><strong>Sanger Sequencing</strong>: Verify exact breakpoint sequences</li><li><strong>ddPCR</strong>: Quantify integration events with high sensitivity</li><li><strong>FISH</strong>: Visualize viral DNA in tissue sections</li><li><strong>Orthogonal Sequencing</strong>: Validate with different platform (PacBio/Nanopore)</li></ul><h3><strong>Example Discoveries</strong></h3><ul><li><strong>MACROD2 Hotspot</strong>: ~10% of cervical cancers have HPV integration in MACROD2</li><li><strong>E2 Breakpoints</strong>: Most integrations disrupt HPV E2 gene</li><li><strong>Clonal Integration</strong>: Early integration events present in all tumor cells</li><li><strong>Gene Fusions</strong>: Viral-host fusions creating chimeric transcripts</li><li><strong>Microhomology</strong>: Integration uses microhomology-mediated repair</li></ul><h3><strong>HPV Types and Cancer Risk</strong></h3><ul><li><strong>High-Risk HPV</strong>: Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59</li><li><strong>HPV16</strong>: Most common in cervical cancer (~55% of cases)</li><li><strong>HPV18</strong>: Second most common (~15%), more adenocarcinomas</li><li><strong>HPV31/33</strong>: Common in head and neck cancers</li><li><strong>Low-Risk HPV</strong>: Types 6, 11 cause warts but rarely cancer</li></ul><h3><strong>Expected Runtime</strong></h3><ul><li><strong>WGS (30x coverage)</strong>: 4-8 hours per sample</li><li><strong>Targeted capture</strong>: 1-2 hours per sample</li><li><strong>Cohort analysis</strong>: Scales linearly with sample count</li><li><strong>Recommended resources</strong>: LARGE node for optimal performance</li></ul><blockquote><p><strong>Perfect for:</strong> HPV Cancer Research • Cervical Cancer Diagnostics • Head & Neck Cancer • Viral Oncogenesis • Biomarker Discovery • Clinical Genomics • Liquid Biopsy • Precision Oncology</p></blockquote>",
  "spec": [
    {
      "type": "Stash File",
      "label": "Input Samplesheet",
      "name": "input",
      "required": true,
      "restrictions": {
        "allow_files": true,
        "allowed_file_types": [
          ".csv",
          ".tsv"
        ]
      }
    },
    {
      "type": "Stash File",
      "label": "Output Directory",
      "name": "outdir",
      "defaultValue": "./viralintegration-results",
      "required": true,
      "restrictions": {
        "allow_files": false,
        "allow_folders": true
      }
    }
  ],
  "jobConfig": [
    {
      "type": "Select",
      "label": "Resources",
      "name": "system_size",
      "options": [
        {
          "label": "LARGE",
          "value": "large",
          "mapValue": {
            "nodeSize": "LARGE",
            "numNodes": 1,
            "withGpu": false
          }
        }
      ],
      "defaultValue": "large"
    }
  ],
  "tags": [
    {
      "name": "viralintegration",
      "type": "task"
    },
    {
      "name": "hpv",
      "type": "task"
    },
    {
      "name": "genomics",
      "type": "task"
    }
  ]
}